Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023
Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.
According to the RNCOS report entitled “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023”, the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.
Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry’s growth.
The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.
According to the RNCOS report entitled “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023”, the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.
Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry’s growth.
The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. ANTIBODY DRUG CONJUGATE (ADC) - AN INTRODUCTION
4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET OUTLOOK TO 2023
5. COMMERCIALIZED ANTIBODY DRUG CONJUGATES
5.1 ADCETRIS
5.2 Kadcyla
5.3 Mylotarg
5.4 Besponsa
6. ANTIBODY DRUG CONJUGATES PIPELINE ANALYSIS
6.1 By Companies
6.1.1 By Clinical Phase
6.1.2 By Indication
6.1.3 By Drug
6.1.4 By Type of Linker
6.1.5 By Technology
6.2 By Research Organizations
6.2.1 By Phase
6.2.2 By Indication
6.2.3 By Drug
6.2.4 By Type of Linker
6.2.5 By Technology
7. DRIVERS AND CHALLENGES
7.1 Drivers
7.1.1 Rising Global Cancer Epidemics
7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
7.1.3 Efforts towards Patent Protection to Drive ADC Market
7.1.4 Increasing Demand for Antibody Drug Conjugates
7.2 Challenges
7.2.1 Production Hurdles and Cost
7.2.2 Inadequacy of Experienced Manufacturers
7.2.3 Regulatory Challenges
8. MAJOR POTENTIAL ANTIBODY DRUG CONJUGATES IN PIPELINE
8.1 By Companies
8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex
8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
8.1.3 Indatuximab Ravtansine/BT-062 – Biotest AG
8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.
8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.
8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
8.2 By Research Organizations
8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital
9. TRENDS AND DEVELOPMENTS
9.1 ADC at the Forefront of Treating Hematological Malignancies
9.2 ADCs Proving Advantageous for Breast Cancer Patients
10. STRATEGIC ALLIANCES IN THE GLOBAL ANTIBODY DRUG CONJUGATES INDUSTRY
11. COMPETITIVE ASSESSMENT
11.1 Seattle Genetics, Inc.
11.2 F. Hoffman-La Roche Ltd.
11.3 Pfizer Inc.
11.4 ImmunoGen, Inc.
11.5 Bayer AG
11.6 Takeda Pharmaceutical Company Limited
11.7 Immunomedics, Inc.
11.8 Oxford BioTherapeutics
11.9 Concortis Biotherapeutics
11.10 NBE-Therapeutics
2. RESEARCH METHODOLOGY
3. ANTIBODY DRUG CONJUGATE (ADC) - AN INTRODUCTION
4. GLOBAL ANTIBODY DRUG CONJUGATES MARKET OUTLOOK TO 2023
5. COMMERCIALIZED ANTIBODY DRUG CONJUGATES
5.1 ADCETRIS
5.2 Kadcyla
5.3 Mylotarg
5.4 Besponsa
6. ANTIBODY DRUG CONJUGATES PIPELINE ANALYSIS
6.1 By Companies
6.1.1 By Clinical Phase
6.1.2 By Indication
6.1.3 By Drug
6.1.4 By Type of Linker
6.1.5 By Technology
6.2 By Research Organizations
6.2.1 By Phase
6.2.2 By Indication
6.2.3 By Drug
6.2.4 By Type of Linker
6.2.5 By Technology
7. DRIVERS AND CHALLENGES
7.1 Drivers
7.1.1 Rising Global Cancer Epidemics
7.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
7.1.3 Efforts towards Patent Protection to Drive ADC Market
7.1.4 Increasing Demand for Antibody Drug Conjugates
7.2 Challenges
7.2.1 Production Hurdles and Cost
7.2.2 Inadequacy of Experienced Manufacturers
7.2.3 Regulatory Challenges
8. MAJOR POTENTIAL ANTIBODY DRUG CONJUGATES IN PIPELINE
8.1 By Companies
8.1.1 Glembatumumab Vedotin Therapeutics/CDX-011 - Celldex
8.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
8.1.3 Indatuximab Ravtansine/BT-062 – Biotest AG
8.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
8.1.5 Polatuzumab Vedotin/RG7596 - F. Hoffman-La Roche Ltd.
8.1.6 DMUC-4064A/RG7882 - F. Hoffman-La Roche Ltd.
8.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
8.2 By Research Organizations
8.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
8.2.2 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital
9. TRENDS AND DEVELOPMENTS
9.1 ADC at the Forefront of Treating Hematological Malignancies
9.2 ADCs Proving Advantageous for Breast Cancer Patients
10. STRATEGIC ALLIANCES IN THE GLOBAL ANTIBODY DRUG CONJUGATES INDUSTRY
11. COMPETITIVE ASSESSMENT
11.1 Seattle Genetics, Inc.
11.2 F. Hoffman-La Roche Ltd.
11.3 Pfizer Inc.
11.4 ImmunoGen, Inc.
11.5 Bayer AG
11.6 Takeda Pharmaceutical Company Limited
11.7 Immunomedics, Inc.
11.8 Oxford BioTherapeutics
11.9 Concortis Biotherapeutics
11.10 NBE-Therapeutics
LIST OF FIGURES:
Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2016, 2017 & 2023
Figure 5-1: Global - ADCETRIS Sales (Million US$), 2016 & 2017
Figure 5-2: Global - Kadcyla Sales (Million US$), 2016 & 2017
Figure 6-1: Global - ADCs Pipeline by Developing Organizations (%), 2017
Figure 6-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2017
Figure 6-3: Global - ADC Pipeline of Companies by Indication (%), 2017
Figure 6-4: Global - ADC Pipeline of Companies by Drug (%), 2017
Figure 6-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2017
Figure 6-6: Global - ADC Pipeline of Companies by Technology (%), 2017
Figure 6-7: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2017
Figure 6-8: Global - ADC Pipeline of Research Organization by Indication (%), 2017
Figure 6-9: Global - ADC Pipeline of Research Organization by Drug (%), 2017
Figure 6-10: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2017
Figure 6-11: Global - ADC Pipeline of Research Organization by Technology (%), 2017
Figure 11-1: F. Hoffman-La Roche Ltd. - Group Sales Breakup by Business Segments (%), 2016
Figure 11-2: Pfizer Inc. - Revenue Breakup by Business Segments (%), 2016
Figure 11-3: Pfizer Inc. - Revenue Breakup by Geography (%), 2016
Figure 11-4: Bayer AG - Sales Breakup by Business Segments (%), 2016
Figure 11-5: Bayer AG - Net Sales Breakup by Geography (%), 2016
Figure 11-6: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016
Figure 11-7: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2017
Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2016, 2017 & 2023
Figure 5-1: Global - ADCETRIS Sales (Million US$), 2016 & 2017
Figure 5-2: Global - Kadcyla Sales (Million US$), 2016 & 2017
Figure 6-1: Global - ADCs Pipeline by Developing Organizations (%), 2017
Figure 6-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2017
Figure 6-3: Global - ADC Pipeline of Companies by Indication (%), 2017
Figure 6-4: Global - ADC Pipeline of Companies by Drug (%), 2017
Figure 6-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2017
Figure 6-6: Global - ADC Pipeline of Companies by Technology (%), 2017
Figure 6-7: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2017
Figure 6-8: Global - ADC Pipeline of Research Organization by Indication (%), 2017
Figure 6-9: Global - ADC Pipeline of Research Organization by Drug (%), 2017
Figure 6-10: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2017
Figure 6-11: Global - ADC Pipeline of Research Organization by Technology (%), 2017
Figure 11-1: F. Hoffman-La Roche Ltd. - Group Sales Breakup by Business Segments (%), 2016
Figure 11-2: Pfizer Inc. - Revenue Breakup by Business Segments (%), 2016
Figure 11-3: Pfizer Inc. - Revenue Breakup by Geography (%), 2016
Figure 11-4: Bayer AG - Sales Breakup by Business Segments (%), 2016
Figure 11-5: Bayer AG - Net Sales Breakup by Geography (%), 2016
Figure 11-6: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016
Figure 11-7: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2017
LIST OF TABLES:
Table 5-1: Global - Incidence of Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
Table 5-2: Global - Incidence of Non-Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
Table 5-3: Major Ongoing Trials for ADCETRIS
Table 5-4: Global - Incidence of Breast Cancer, 2012, 2015, 2020, & 2025
Table 5-5: Major Ongoing Trials for Kadcyla
Table 5-6: Major Ongoing Trials for Mylotarg
Table 5-7: Major Ongoing Trials for Besponsa
Table 6-1: Global - ADC Pipeline of Companies
Table 6-2: Global - ADC Pipeline of Research Organization
Table 10-1: Major Strategic Alliances in the Global Antibody Drug Conjugates Industry (2014-2017)
Table 11-1: Seattle Genetics, Inc. - Key Financials (Million US$), 2014-2016
Table 11-2: Seattle Genetics, Inc. - ADC Product Portfolio
Table 11-3: Seattle Genetics, Inc. - ADCs in Pipeline
Table 11-4: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2014-2016
Table 11-5: F. Hoffman-La Roche Ltd. - ADC Product Portfolio
Table 11-6: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
Table 11-7: Pfizer Inc. - Key Financials (Million US$), 2014-2016
Table 11-8: Pfizer Inc. - ADC Product Portfolio
Table 11-9: Pfizer Inc. - ADCs in Pipeline
Table 11-10: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
Table 11-11: ImmunoGen, Inc. - ADCs in Pipeline
Table 11-12: Bayer AG - Key Financials (Million US$), 2014-2016
Table 11-13: Bayer AG - ADCs in Pipeline
Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
Table 11-15: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
Table 11-16: Immunomedics, Inc. - Key Financials (Million US$), 2015-2017
Table 11-17: Immunomedics, Inc. - ADCs in Pipeline
Table 11-18: Oxford BioTherapeutics - ADCs in Pipeline
Table 11-19: Concortis Biotherapeutics - ADCs in Pipeline
Table 11-20: NBE-Therapeutics - ADCs in Pipeline
Table 5-1: Global - Incidence of Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
Table 5-2: Global - Incidence of Non-Hodgkin Lymphoma, 2012, 2015, 2020, & 2025
Table 5-3: Major Ongoing Trials for ADCETRIS
Table 5-4: Global - Incidence of Breast Cancer, 2012, 2015, 2020, & 2025
Table 5-5: Major Ongoing Trials for Kadcyla
Table 5-6: Major Ongoing Trials for Mylotarg
Table 5-7: Major Ongoing Trials for Besponsa
Table 6-1: Global - ADC Pipeline of Companies
Table 6-2: Global - ADC Pipeline of Research Organization
Table 10-1: Major Strategic Alliances in the Global Antibody Drug Conjugates Industry (2014-2017)
Table 11-1: Seattle Genetics, Inc. - Key Financials (Million US$), 2014-2016
Table 11-2: Seattle Genetics, Inc. - ADC Product Portfolio
Table 11-3: Seattle Genetics, Inc. - ADCs in Pipeline
Table 11-4: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2014-2016
Table 11-5: F. Hoffman-La Roche Ltd. - ADC Product Portfolio
Table 11-6: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
Table 11-7: Pfizer Inc. - Key Financials (Million US$), 2014-2016
Table 11-8: Pfizer Inc. - ADC Product Portfolio
Table 11-9: Pfizer Inc. - ADCs in Pipeline
Table 11-10: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
Table 11-11: ImmunoGen, Inc. - ADCs in Pipeline
Table 11-12: Bayer AG - Key Financials (Million US$), 2014-2016
Table 11-13: Bayer AG - ADCs in Pipeline
Table 11-14: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
Table 11-15: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
Table 11-16: Immunomedics, Inc. - Key Financials (Million US$), 2015-2017
Table 11-17: Immunomedics, Inc. - ADCs in Pipeline
Table 11-18: Oxford BioTherapeutics - ADCs in Pipeline
Table 11-19: Concortis Biotherapeutics - ADCs in Pipeline
Table 11-20: NBE-Therapeutics - ADCs in Pipeline
